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Ebolavirus causes severe hemorrhagic fever in humans and non-human primates. Entry of ebolavirus is
mediated by the viral glycoprotein, GP; however, the required host factors have not been fully
elucidated. A screen utilizing a recombinant Vesicular Stomatitis Virus (VSV) encoding Zaire ebolavirus
GP identiﬁed four Chinese Hamster Ovary (CHO) cell lines resistant to GP-mediated viral entry.
Susceptibility to vectors carrying SARS coronavirus S or VSV-G glycoproteins suggests that endocytic
and processing pathways utilized by other viruses are intact in these cells. A cathepsin-activated form
of the ebolaviral glycoprotein did not overcome the entry restriction, nor did expression of several host
factors previously described as important for ebolavirus entry. Conversely, expression of the recently
described ebolavirus host entry factor Niemann–Pick Type C1 (NPC1) restored infection. Resistant cells
encode distinct mutations in the NPC1 gene, resulting in loss of protein expression. These studies
reinforce the importance of NPC1 for ebolavirus entry.
& 2012 Elsevier Inc. All rights reserved.Introduction
Ebolavirus is a non-segmented, negative-sense RNA virus of
the Filoviridae family that is associated with outbreaks of hemor-
rhagic fever in humans and non-human primates in sub-Saharan
Africa. Ebolavirus infects a wide range of cell types during an
infection, including macrophages, dendritic cells, and hepato-
cytes. Entry into cells is mediated through the viral glycoprotein
(GP), but the process is poorly characterized. Recent studies
suggest that the virion enters the cell through macropinocytosis
(Hunt et al., 2010; Nanbo et al., 2010; Saeed et al., 2010).
Although the trigger for this uptake is not known, several host
factors have been identiﬁed that could be involved in this step
(Hunt et al., 2010; Kondratowicz et al., 2011). Once in the
endosome, the virion encounters the cysteine proteases Cathepsin
B (CatB) and Cathepsin L (CatL). These proteases cleave GP within
a disordered loop (Chandran et al., 2005; Kaletsky et al., 2007;
Schornberg et al., 2006). Although this cleavage appears to be
necessary for entry, it is not sufﬁcient to induce viral fusion with
the host membrane. A subsequent step requiring cathepsins is
also necessary (Kaletsky et al., 2007; Schornberg et al., 2006). The
substrate of this second cathepsin cleavage has not been deﬁned.
Recently, Niemann–Pick Type C1 (NPC1) was identiﬁed as a hostll rights reserved.
ates).protein important for entry of Ebola virus (Carette et al., 2011;
Cote et al., 2011). NPC1 is thought to interact with the processed
form of GP (Cote et al., 2011), but a mechanism of action has not
been determined.
The lack of knowledge about host factors involved in entry of
ebolavirus has hindered the development of therapeutics target-
ing this process. Several different screening strategies have been
used in the past to identify host factors involved in entry, with
varying success. Chinese Hamster Ovary K1 (CHO-K1) cells are a
functionally haploid cell line that is naturally genetically diverse.
For decades, these properties of CHO-K1 cells have been exploited
to isolate variants with alterations in speciﬁc processes, such as
diphtheria intoxication (Moehring and Moehring, 1977). Such
variants were subsequently used to elucidate the mechanism of
the given process being studied.
Here we describe the isolation of CHO-K1 cell lines with
natural mutations rendering the cells resistant to infection
mediated by ebolavirus GP. Multiple clones derived from inde-
pendent selections were obtained, and four were chosen for
further characterization. The cell lines were analyzed for defects
in established host factors involved in ebolavirus entry, and all
four were found to have a defect in expression of NPC1. Exogen-
ous expression of NPC1 restored susceptibility to infection in all
four clones. Additionally, overexpression of several other pur-
ported ebolavirus entry factors did not overcome a defect in
NPC1. Although NPC1 is not expressed in any of these clones, the
mutations leading to this loss of expression are unique in each
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natural mutations in the NPC1 gene lends weight to the recent
evidence suggesting that NPC1 is a key host factor necessary for
entry of ebolavirus.Results
Isolation of CHO-K1 clones resistant to GP-mediated entry
A replication competent VSV encoding ebolavirus Zaire
(ZEBOV) GP and mCherry in place of VSV G was constructed.
Cellular entry of this recombinant virus, VSV EboGP mCherry, is
mediated by the ebolaviral glycoprotein, similar to a previously
described vaccine virus, VSVDG/ZEBOV GP (Feldmann et al., 2007;
Garbutt et al., 2004; Jones et al., 2005). The ebolavirus GP
requirement for entry was conﬁrmed through loss of infection
in the presence of lysosomotropic reagents and CatB- and CatL-
speciﬁc inhibitors (data not shown). Infection of susceptible cells
with this recombinant virus results in efﬁcient killing and is the
basis for the selection strategy employed below.
The functionally haploid cell line CHO-K1 was used to identify
cells resistant to infection with VSV EboGP mCherry using the
strategy outlined in Fig. 1a. Infection of unmutagenized CHO cells
with VSV EboGP mCherry at an MOI of 8 produced numerous
colonies. In contrast, infection with VSV-GFP, a VSV vector
expressing its own glycoprotein and a GFP marker, did not
produce any viable colonies. This observation suggests that there
is a high level of natural resistance to ebolaviral entry in CHO
cells. After expansion, colonies were pooled and cloned byInfect CHO-K1 cells with VSV EboGP mCherry
 in 10cm plates (MOI = 8)
Transfer colonies to 96 well plates 
and allow to expand
Passage plates for 3 weeks
Re-plate at one cell/well in 96 well
Re-challenge clones derived from single cell
with VSV EboGP mCherry and VSV GFP
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Fig. 1. Isolation of cell lines resistant to GP-mediated infection. (a) Selection
method for isolating CHO-K1 cells resistant to GP-mediated infection. (b) Resistant
cell lines were challenged with VSV GFP or VSV EboGP mCherry. Percent cells
infected was quantitated by ﬂow cytometry. Bars represent average of means from
three experiments done in triplicate; error bars represent standard error means.limiting dilution. Clonal cell lines were tested for susceptibility
to VSV EboGP mCherry and VSV GFP. Four clonal cell lines (R1, R2,
R4, and L2) that displayed complete resistance to VSV EboGP
mCherry, while maintaining susceptibility to VSV GFP, were
chosen for further characterization. These four cell lines were
derived from resistant colonies isolated from separate plates
challenged with VSV EboGP mCherry. The R2 and L2 cell lines
display a similar morphology to wildtype (WT) CHO-K1 cells
while R1 cells are much larger than WT cells with a more
ﬁbroblast-like appearance, and the R4 cells are larger and rounder
than the CHO-K1 parent.
The susceptibility proﬁles for clones R1, R2, R4, and L2 were
conﬁrmed by examining expression of mCherry or GFP via light
microscopy at varying time points post-infection (PI) with VSV
EboGP mCherry or VSV GFP, respectively (data not shown).
Beginning 6–8 h PI, GFP is visible for R1, R2, R4, L2, and WT
CHO-K1 cells infected with VSV GFP. By 24 h PI all cells are
infected and most show a cytopathic effect from VSV replication.
Infection of WT CHO-K1 cells with VSV EboGP mCherry produces
a similar pattern. In contrast, for the R1, R2, R4, and L2 cell lines
neither expression of the mCherry marker nor the cytopathic
effects of VSV replication is seen with either high or low MOIs of
VSV EboGP mCherry at any time point up to 48 h post-infection.
Given the rapid kinetics of VSV replication in these cells, even low
levels of infection would be apparent by 48 h. A more quantitative
analysis using ﬂow cytometry demonstrates that all four cell lines
are effectively infected with VSV GFP (Fig. 1b). On the contrary,
while an average of 33% of WT CHO-K1 cells express mCherry
12 h after challenge with VSV EboGP mCherry, less than 0.2% of
R1, R2, R4, and L2 cells express mCherry (Fig. 1b). This data
indicates that the R1, R2, R4, and L2 cells are resistant to infection
mediated by Zaire ebolavirus GP, but not VSV G.
CHO-K1 clones are resistant to transduction with HIV pseudotypes
bearing ZEBOV GP, but not VSV G
To ensure that the resistance of these clones was speciﬁc for
GP-mediated entry, we examined whether the clones were
susceptible to transduction with HIV pseudotypes encoding GFP
and bearing VSV G (HIV/VSV G) or Zaire ebolavirus GP (HIV/
ZEBOV GP). Cells were ﬁxed 48 h PI and analyzed by ﬂow
cytometry for GFP expression. All four resistant clones had similar
levels of transduction with HIV/VSV G as WT CHO-K1 cells, as
determined by the percent of cells expressing GFP (Fig. 2a). In
contrast, while on average approximately 26% of WT CHO-K1 cells
expressed GFP following transduction with HIV/ZEBOV GP, less
than 2% of the resistant cells were transduced. This represents
less than ten percent of the level of transduction of WT CHO-K1
cells (Fig. 2a). A similar result was seen when the resistant cells
were challenged with HIV pseudotypes bearing Sudan ebolavirus
(SEBOV) GP, Cote d’Ivoire ebolavirus (CIEBOV) GP, or Reston
ebolavirus (REBOV) GP (Fig. 2b). There was no statistically
signiﬁcant difference in the level of infection for each cell line
when comparing across ﬁloviral glycoproteins. Taken together,
these data indicate that the resistance to infection observed for
R1, R2, R4, and L2 cells is speciﬁc for ﬁloviral GP-mediated entry.
Ebolavirus GP is normally processed by endosomal cathepsins
during entry into the host cell. This cleavage is believed necessary
to activate the fusogenic potential of GP. To test whether the
resistance to infection in the isolated CHO cell lines was due to a
defect upstream of the ebolavirus GP proteolysis step, we chal-
lenged the resistant cells with an HIV pseudotype bearing a
mutant form of GP that mimics processed GP (GP0, Fig. 2a). This
mutant form, GP0, contains a furin recognition sequence, RRKR, at
amino acids 203–206 (Fig. S1a). In the presence of furin, GP0 is
cleaved at amino acid 207, producing a GP1 fragment that is six
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Fig. 2. Resistance is speciﬁc to GP-mediated infection. Resistant cell lines were
challenged with HIV pseudotypes encoding GFP and bearing VSV G, ZEBOV GP,
ZEBOV GP0 (a) SEBOV GP, CIEBOV GP, or REBOV GP (b). Percent cells transformed
was quantitated by ﬂow cytometry. Bars represent average of means from three or
four experiments done in triplicate; error bars represent standard error means.
Asterick indicates statistically signiﬁcant difference in infection level between GP
and GP0 (p¼0.04).
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Fig. 3. Pseudotypes bind equally well to resistant cell lines and WT CHO-K1 cells.
HIV pseudotypes bearing ZEBOV GP or VSV G were centrifuged onto cells at 4 1C.
Unbound virus was washed away and cell lysates were collected. The percent of
particles that bound to the cell surface was determined by comparing HIV p24
levels in the cell lysates to the amount of input virus by quantitative ﬂuorescent
Western blot. Bars represent average of means from three experiments done in
triplicate; error bars represent standard error means.
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Cells were transduced with HIV/ZEBOV GP0 pseudotypes
encoding GFP and analyzed by ﬂow cytometry. Although GP0
incorporates into HIV virions at a ratio of approximately 0.5:1
compared to WT GP, pseudotypes bearing GP0 are more infectious
(see Fig. 2a, WT cells). The increased susceptibility of WT CHO-K1
cells to HIV/ZEBOV GP0 (average of 45% of cells infected compared
to 26% with WT GP) was not seen in the resistant cell lines. The
lack of an increase in susceptibility for the resistant cell lines
indicates that the resistance to infection seen in these cell lines
could not be overcome by prior cleavage of ebolavirus GP
(Fig. 2a).
Resistant CHO-K1 cells can bind ZEBOV GP-bearing virus at similar
levels to that of WT CHO-K1 cells
To determine whether these cell lines are resistant due to
reduced viral binding to the cell surface, we performed a binding
assay with HIV/VSV G and HIV/ZEBOV GP. Virus was spun onto
cells at 4 1C, followed by washes with cold PBS to remove any
unbound virus prior to lysing the cells. Cell lysates were analyzed
by quantitative Western blot for HIV p24 levels and compared to
a viral input control. The level of binding of HIV/VSV G and HIV/
ZEBOV GP pseudotypes to the R1, R2, R4, and L2 cell lines was not
statistically signiﬁcant compared to WT CHO-K1 cells (Fig. 3),
indicating that binding efﬁciency is not altered in the
resistant cells.
Cell lines expressing active forms of cathepsin B and cathepsin L
remain resistant to ebolavirus entry
As mentioned above, ﬁloviruses require cleavage of GP by CatB
and/or CatL to infect cells. Therefore, we tested whether the R1,R2, R4, and L2 cell lines were resistant to GP-mediated infection
due to a loss of expression of CatB or CatL. Cells were transfected
with a human CatB or human CatL expression plasmid, challenged
with VSV EboGP mCherry, and analyzed by ﬂow cytometry. Fig. 4c
represents the combined results from three separate experiments.
While the percent of cells expressing mCherry was similar to
background levels for all conditions with the resistant cell lines, in
two of the three experiments there was a small but statistically
signiﬁcant increase in infection for the R4 cells when comparing
empty vector to CatL transfected cells (Fig. 4c). However, the
percent of cells expressing mCherry was still less than 1%,
suggesting that this minor increase is likely not biologically
relevant. The lack of infection of R1, R2, R4, and L2 cells in the
presence of overexpression of CatB or CatL indicated that a loss of
expression of CatB or CatL is not the cause for the resistance to
GP-mediated infection. However, this analysis did not rule out the
possibility that the cells lacked the ability to activate CatB or CatL.
Activation of CatB and CatL requires two sequential processing
steps of their procathepsin form to a double chain form. All three
forms of the protein, the procathepsin (Pro), the single chain (SC)
and the fully active double chain (DC), can be visualized by
Western blot analysis using cathepsin antibodies. To determine
whether the R1, R2, R4, and L2 cells are capable of processing
cathepsins into their active forms, lysates from cells transfected
with human CatB or CatL expression plasmids were analyzed by
Western blot. Transfected R1, R2, R4, and L2 cells express all three
forms of human CatB, indicating that CatB is fully processed in
these cells (Fig. 4a). The antibody against CatL recognizes both
human and hamster CatL. Therefore, the banding pattern on a
Western blot is more complex. However, as can be seen in Fig. 4b,
all four resistant clones clearly expressed the active form of
endogenous CatL. Together, this data suggests that R1, R2, R4,
and L2 cells can process CatB and CatL into their active forms.
Similar to ﬁloviruses, severe acute respiratory syndrome
(SARS) coronavirus (CoV) requires cleavage of its glycoprotein,
spike (S), by CatL to enter cells (Simmons et al., 2005). Therefore,
to directly address whether the cathepsin pathway in R1, R2, R4,
and L2 cells can function to activate viral glycoproteins, we
challenged the ebolavirus resistant clones with VSV pseudotypes
encoding luciferase and bearing SARS-CoV S or ZEBOV GP. Chinese
hamster cells lack functional surface receptors for SARS-CoV.
Accordingly, the ebolavirus-resistant cell lines were transiently
transfected with an expression plasmid for human ACE2, the
receptor for SARS-CoV, 48 h prior to transduction with VSV/SARS
S or VSV/ZEBOV GP. Untransfected cells were also challenged with
VSV/SARS S as a negative control. R1, R2, R4, and L2 cells
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Fig. 4. Resistant cells do not have defect in CatB or CatL. Overexpression of human CatB (a) or human CatL (b) in resistant cell lines. The procathepsin (Pro), single chain
(SC), and double chain (DC) forms are indicated. (c) Resistant cell lines were transiently transfected with an expression plasmid for human CatB or CatL and challenged
with VSV EboGP mCherry. Percent cells infected was quantitated by ﬂow cytometry. Bars represent averages from three experiments done in triplicate, error bars represent
standard error mean. Asterick indicates statistically signiﬁcant difference in infection level between CatL and empty vector, p¼0.03. (d) Transduction of WT CHO-K1 cells
and resistant cell lines with VSV pseudotypes bearing ZEBOV GP or SARS S, as measured by Renilla luciferase activity. Bars represent average of means from three
experiments done in triplicate; error bars represent standard error means.
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following challenge with VSV/SARS S (Fig. 4d). Conversely, as
before, these cell lines were refractory to transduction mediated
by ebolavirus GP, with only background levels of luciferase
activity seen following challenge with VSV/ZEBOV GP. These
background luciferase values for the mutant cells lines were not
statistically different compared to those seen with VSV/SARS S
transduction in the absence of human ACE2. The high level of
transduction of all four clones with VSV/SARS S indicates that the
endosomal uptake and CatL pathways are intact and do not
appear to be the mechanism for resistance of these cell lines.
Overexpression of Axl or TIM-1 does not rescue infectivity
In addition to the cathepsins, several other host factors have
been identiﬁed as potentially important for ebolavirus GP-
mediated entry, including Axl and TIM-1 (Brindley et al., 2011;
Kondratowicz et al., 2011; Shimojima et al., 2007, 2006). To
determine if the ebolavirus-resistant cell lines had a defect in
either of these proteins, we transfected WT, R1, R2, R4, and L2
cells with expression plasmids for Axl and TIM-1. Expression of
Axl and TIM-1 was conﬁrmed, and the cells were subsequently
infected with VSV EboGP mCherry and analyzed by ﬂow cytome-
try. Similar to earlier results seen with overexpression of CatB and
CatL, the level of infection for all of the ebolavirus resistant cell
lines was not statistically signiﬁcant when comparing cells
expressing Axl or TIM-1 versus empty vector (Fig. 5). This
indicates that a defect in expression of Axl or TIM-1 is likely notthe cause of the resistance of the R1, R2, R4, and L2 clones.
Moreover, expression of these factors cannot compensate for the
deﬁcit in the ebolavirus-resistant cells.All resistant clones have mutations in the NPC1 gene
Recently the endosomal-resident protein NPC1 was shown to
be important for Ebola infection (Carette et al., 2011; Cote et al.,
2011). Therefore, we analyzed the resistant CHO-K1 cell lines for
defects in NPC1 expression. Expression of full-length NPC1 is
readily evident by Western blot analysis of WT CHO-K1 cells
(Fig. 6b) whereas no expression is seen in the four ebolavirus-
resistant cell lines. To determine the basis for the loss of expres-
sion of NPC1 in the resistant cells we performed RT-PCR on total
cellular RNA. Sequence analysis of the cDNA for three of the
clones, R1, R2, and L2, reveals that they contain unique frameshift
mutations in the NPC1 gene. The R1 cell line encodes an
8-nucleotide (nt) duplication in exon 12, starting at nt 1832 and
resulting in a truncated protein predicted to be 624 amino acids
long. The R2 cell line contains an 874-nt insertion in exon
8 ﬂanked by a 3-nt repeat (see Fig. 6a). This insert results in a
predicted 466 aa product. L2 contains a substitution (P98S) in
exon 4 and a 20-nt deletion in exon 6. The deletion results in a
truncation of the protein after NPC1 residue number 225. RT-PCR
analysis using several sets of primers failed to detect an intact
transcript encoding NPC1 in the R4 cell line, suggesting there is a
large deletion or major rearrangement of the locus in these cells.
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Fig. 5. Overexpression of Axl or TIM-1 does not restore susceptibility. Resistant
cell lines were transiently transfected with an expression plasmid for human Axl
(a) or human TIM-1 (b) challenged with VSV EboGP mCherry, and analyzed by
ﬂow cytometry for expression of mCherry. Bars represent means from two
experiments done in triplicate; error bars represent standard error means.
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R2, R4, and L2 cell lines is the cause for their ebolavirus-resistant
phenotype, we generated cells that stably express human NPC1. A
lentiviral vector encoding the Hygromycin B resistance gene and
NPC1 or GFP was used to transduce parental WT CHO-K1 and the
four resistant cell lines. Hygromycin B selected cells were used for
protein analysis by Western blot or challenged with VSV EboGP
mCherry and analyzed by ﬂow cytometry. Varying, but readily
detectable, levels of NPC1 were seen in all of the Hygromycin
selected cell lines (Fig. 6b). In all cases, stable expression of NPC1
was able to at least partially restore susceptibility to ebolavirus
GP-mediated infection (Fig. 6c). The transduced R1, R2, and L2 cell
lines were infected by VSV EboGP mCherry at roughly 49–60%
that of WT cells (Fig. 6c). While the restoration of susceptibility
was less efﬁcient in the R4 line, with an average infection level of
about 19% of WT, this level was still approximately100-fold above
that seen without NPC1 expression. A similar trend with the R4
clone showing the lowest degree of restoration was seen when
the cells transiently expressed NPC1 (data not shown). By
comparison, stable expression of NPC1 in M12 cells, a CHO cell
line carrying a deletion of the NPC1 locus (Millard et al., 2000),
resulted in 40% level of infection in WT cells. While the basis for
the varying degrees of susceptibility in the transduced cells is
unclear, these results demonstrate that restoration of NPC1
expression in these cell lines confers susceptibility to ebolavirus
infection.Discussion
Multiple screening strategies, including genetic complementa-
tion and comparative gene expression analysis, have been used in
the past to identify host factors important for entry of ebolavirus.
Often the results were ambiguous, with only a modest increase ininfection seen in the presence of the host factor. In some instances
the predicted host factor was not expressed in all susceptible cell
types (Chan et al., 2001; Kondratowicz et al., 2011).
In this study we employed an alternative approach by select-
ing for natural mutations that rendered cells normally susceptible
to infection resistant. Because CHO-K1 cells are functionally
haploid at most alleles, a mutation in a single allele of a gene is
likely to result in a phenotypic effect on the affected protein. By
not mutagenizing the cells prior to selection, we limited our
screen to naturally occurring mutations that disrupted a function
vital for viral entry. In doing so, we also increased the likelihood
of selecting for genetic variants with mutations in a single gene.
Four independent cell lines that demonstrated complete resis-
tance to infection with VSV EboGP mCherry were identiﬁed and
selected for further characterization.
Previously, another CHO-K1 clone, CHO B2, was also shown to
be resistant to ebolavirus GP-mediated entry (Schornberg et al.,
2009). This resistance was attributed to a defect in processing of
CatB and CatL caused by a lack of expression of a5b1 integrin on
the cell surface. Unlike CHO B2 cells, our cell lines express the
active, DC form of CatB and CatL. Furthermore, the R1, R2, R4, and
L2 cell lines are susceptible to infection by pseudotypes bearing
the SARS CoV spike protein, conﬁrming that both endosomal
internalization and CatL are functional in these cells. Although
there was a slight, albeit statistically signiﬁcant, increase in
susceptibility of the R4 cell line to VSV EboGP mCherry when
human CatL was overexpressed, the level of infection was still less
than one percent, suggesting that the increase is not biologically
relevant.
Several host factors, in addition to CatL and CatB, have been
identiﬁed previously as being important for GP-mediated entry of
Ebola, including Axl and TIM-1 (Brindley et al., 2011;
Kondratowicz et al., 2011; Shimojima et al., 2007, 2006). Over-
expression of these proteins in our resistant cell lines did not
restore susceptibility, suggesting that the R1, R2, R4, and L2 cells
do not have a defect in either of these genes. Recent evidence
demonstrates that Axl can facilitate entry of some viruses by a
Gas6/phosphatidylserine mediated mechanism resembling apop-
totic body uptake, and this process is most evident when a
primary entry pathway is disrupted or impaired (Morizono
et al., 2011). Axl can also provide an alternative entry pathway
for Lassa virus in cells deﬁcient for the primary receptor a-
dystroglycan by a process that does not require Gas6
(Shimojima et al., 2012). Our results indicate that Axl overexpres-
sion does not provide an alternative means of entry into NPC1
deﬁcient, ebolavirus-resistant mutant CHO-K1 cell lines.
During entry into target cells, ebolavirus likely uses multiple
host factors to accomplish the steps of attachment, uptake,
trafﬁcking, and fusion. Defects in host proteins involved in any
of these steps could potentially confer cellular resistance to
infection. Consequently, the relatively unbiased selection method
employed here could result in isolation of mutants with defects in
several different genes, as was seen with a similar screen looking
at diphtheria toxin resistance (Moehring and Moehring, 1977).
However, all four of the independently isolated ebolavirus GP-
resistant CHO cell lines contained mutations in the same gene,
NPC1. Although all of the resistant cell lines characterized had
mutations in NPC1, the mutations were all unique, indicating that
they arose from discrete events. Furthermore, exogenous expres-
sion of NPC1 restored susceptibility of the resistant cells, indicat-
ing that the loss of expression of NPC1 was sufﬁcient to render
these cells resistant. It is possible that these resistant cell lines
could have an additional defect in another gene. However, given
the high level of restoration seen with exogenous expression of
NPC1, any such mutation is likely to only play a minor role, if any,
in susceptibility to entry.
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Fig. 6. Resistant cell lines have mutations in NPC1. (a) Schematic of NPC1 protein. Location of insertions in R1 (star) and R2 (circle), and deletion (triangle) and substitution
(diamond) in L2 indicated in diagram at top and in sequence at bottom. (b) Expression of NPC in WT, M12, and resistant cells transduced with pLenti CMV NPC1 Hygro or
pLenti CMV GFP Hygro. (c) Resistant cells stably expressing NPC1 or GFP were challenged with VSV EboGP mCherry and infection was quantitated by ﬂow cytometry. Bars
represent average of means from three separate experiments done in triplicate; errors bars represent standard error means.
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component in ebolavirus GP-mediated infection (Carette et al.,
2011; Cote et al., 2011). Carette et al. used an insertional
mutagenesis approach to identify cells resistant to infection by
ebolavirus GP. Although they utilized a recombinant VSV-EboGP
vector similar to the one employed here, the insertional muta-
genesis strategy employed could have biased the results toward
NPC1 because of the large target size (455 kilobases) of the NPC1
gene. Similarly, the studies by Cote and colleagues used a
compound library screen to identify NPC1, and thus were biased
toward ‘‘druggable’’ targets. Our ﬁndings, using a selection strat-
egy with a bias for naturally occurring mutations, also identiﬁed
NPC1 in multiple ebolavirus-resistant cell lines. Despite perform-
ing a selection screen with VSV-EboGP using four independent
pools of CHO-K1 cells, and in contrast to the selection screen of
Carette et al. (2011), the current studies did not identify any other
targets of ebolavirus entry aside from NPC1. The fact that our
screen did not identify the HOPS (hemolytic fusion and protein
sorting) endosomal sorting complex proteins found by Carette
et al. (2011) may suggest that CHO cells with defects in these
genes are rare or that the screen was not saturating. Taken as a
whole, three strategies, each with a different selection bias,
identiﬁed the same host factor, conﬁrming the critical role of
NPC1 in Ebola entry.NPC1, an important player in cholesterol homeostasis, is a
1278-amino acid protein that has 13 predicted membrane-span-
ning domains and is normally localized within late endosomes.
Mutational analysis of NPC1 in human patients has revealed over
100 different alterations, widely distributed throughout the gene,
which affect cholesterol regulatory function (Carstea et al., 1997;
Garver and Heidenreich, 2002). The majority are missense muta-
tions, several of which result in essentially normal amounts of
NPC1 protein but impair cholesterol control (Millat et al., 2001;
Ribeiro et al., 2001). Missense and deletion mutations that affect
NPC1 localization to the late endosome have also been identiﬁed
(Blom et al., 2003). However, in our studies all of the CHO
mutants selected for resistance to ebolavirus GP abrogated
NPC1 protein expression. This suggests that simple mutations
that impair the cholesterol regulatory function of NPC1 do not
cripple the protein’s role in ebolaviral entry.Conclusions
We demonstrate that CHO cells selected for resistance to
infection mediated by the ebolavirus glycoprotein harbor defects
in NPC1. In four independent cell lines examined, the mutation
within the NPC1 gene aborgates expression of the NPC1 protein
K.M. Haines et al. / Virology 432 (2012) 20–2826and restoration of protein expression restores sensitivity to
ebolavirus GP mediated infection. These results underscore the
importance of NPC1 in ebolaviral entry.Materials and methods
Cell culture and plasmids
CHO-K1 cells were maintained in Kaighn’s modiﬁed F-12K
nutrient mixture with 10% heat-inactivated fetal bovine serum
(FBS), L-glutamine, penicillin, and streptomycin. M12 cells were
kindly provided by Daniel Ory (Millard et al., 2000). BHK cells
were maintained in Eagle’s Minimum Essential Medium (MEM)
with 10% FBS, penicillin, and streptomycin. Vero and 293T cells
were maintained in high glucose Dulbecco’s modiﬁed Eagle’s
medium (DMEM) with 10% FBS, penicillin, and streptomycin. All
cultures were grown in 5% CO2.
pCAGGS-EboGP-V5 (strain Zaire 1976 Mayinga), pCB6-VSV G,
pCB6-EboZ GP, pCAGGS SARS S and pSPAX have been previously
described (Simmons et al., 2002, 2004). pCAGGS-EboGPrrkr-V5
was generated by site directed mutagenesis of pCAGGS-EboGP-
V5. pLenti CMV GFP Hygro, hCathepsinL, and hCathepsinB were
obtained from Addgene (Cambridge, MA). The cDNA for TIM-1
was obtained from Open Biosystems and was cloned into pLKO by
PCR. VSV-XN2 rLuc, VSV-L, VSV-N, and VSV-P expression plas-
mids, all under the control of the T7 promoter, were kindly
provided by Robert Doms. VSV-XN2 EboGP mCherry was made
by overlapping extension PCR. The ﬂanking primer at the 50 end
contained an MluI restriction site and was used to amplify
ebolavirus Zaire GP. The ﬂanking primer at the 30 end contained
an NheI restriction site and was used to amplify mCherry. The
internal primers were designed such that an additional junction
sequence, ﬂanked by KpnI and XhoI, was inserted between GP and
mCherry. The rLuc gene was removed from VSV-XN2 rLuc by
cleavage with MluI and NheI and replaced with the GP-KpnI-
junction-XhoI-mCherry sequence. pLenti CMV NPC1 Hygro was
constructed by removing the GFP gene from pLenti CMV GFP
Hygro and inserting into its place the NPC1 cDNA (Origene).
pSport6 Axl (clone ID 5205825) was from Open Biosystems.
pcDNA3.1 furin and pcDNA3.1-ACE2 were previously described
(Simmons et al., 2005; Wool-Lewis and Bates, 1999).
Generation of VSV EboGP mCherry
VSV EboGP mCherry was generated using a protocol similar to
that described in Lawson et al. with the following changes
(Lawson et al., 1995). Brieﬂy, early passage BHK cells were
infected with Modiﬁed Vaccinia Ankara T7 (MVA-T7), a gift from
Bernard Moss. After 30 min cells were transfected with VSV-XN2
EboGP mCherry, pVSV-N, pVSV-L, and pVSV-P using Lipofecta-
mine 2000 (Invitrogen). Three days post-transfection cells were
scraped from the dish. Cells and supernatant were subjected to
three rounds of freeze-thawing. The resulting mixture was spun
at 1250g to remove cellular debris and then passed through a
0.2 um ﬁlter before being added to naı¨ve BHK cells. Clariﬁed and
ﬁltered supernatant was passaged onto BHK cells two additional
times. After three rounds of infection on BHK cells, supernatant
was transferred to naı¨ve Vero cells along with neutralizing
antibodies (VMC-2 and VMC-25, kindly provided by Gary Cohen
and Roz Eisneberg) against Vaccinia. Antibodies were included in
two additional passages on Vero cells to ensure removal of MVA.
Working stocks of VSV EboGP mCherry and VSV GFP were
expanded on Vero cells grown in 850 cm2 roller bottles. Super-
natant was clariﬁed by centrifugation at 1250g for 5 min followed
by ultracentrifugation at 6000 rpm in an SW28 rotor for 10 min at4 1C. Supernatant was then transferred to new tubes and con-
centrated through a 20% sucrose cushion by ultracentrifugation at
28,000 rpm for two hours in an SW28 rotor at 4 1C. Viral Pellets
were resuspended in hepes-buffered saline (HBS) at 4 1C over-
night and stored at 80 1C. Concentrations for both viral stocks
were determined by plaque assay on Vero cells. VSV GFP was
kindly provided by Sara Cherry.
Isolation of ebolavirus GP-resistant CHO-K1 cells
CHO-K1 cells were plated in 10 cm plates. At 85% con-
ﬂuency, cells were infected with VSV EboGP mCherry at an MOI
of 8. Plates were maintained for three weeks until resistant
colonies contained between 100 and 500 cells. Colonies were
transferred to 96-well plates using sterile paper discs soaked in
trypsin. Cells were allowed to grow to conﬂuence before being re-
plated at approximately one cell per well of a 96-well plate.
Clones were expanded and challenged separately with VSV EboGP
mCherry and VSV GFP. Four cell lines, R1, R2, R4, and L2,
originating from resistant colonies isolated from separate 10 cm
plates, were chosen for further analysis.
Pseudovirion preparation
To make human immunodeﬁciency virus (HIV) pseudotypes,
293T cells were transfected using a standard calcium phosphate
method with 8 mg of the HIV vector pSPAX, 8 mg of pLenti CMV
GFP Hygro, and either 6 mg of pCB6-VSV G or 10 mg of pCAGGS-
Ebola GP-V5. For HIV/ZEBOV GPrrkr, 8 mg of pSPAX, 8 mg of pLenti
CMV GFP Hygro, 20 mg of pCAGGS-Ebola GPrrkr-V5, and 4 mg of
pcDNA3.1 furin were used. Viral supernatants were collected 48 h
post-transfection and concentrated through a 20% sucrose cush-
ion by ultracentrifugation at 28,000 rpm in an SW28 rotor for 2 h
at 4 1C. Pellets were resuspended in HBS at 4 1C overnight.
Incorporation of ebolavirus glycoproteins was determined by
quantitative western blotting with either a polyclonal anti-V5
rabbit antibody (Bethyl) or a polyclonal anti-GP1 rabbit anti-
serum. VSV pseudotypes were made by Graham Simmons as
previously described (Ray et al., 2010). Brieﬂy, 293T cells were
transfected with pCAGGS SARS S or pCB6-EboZ GP 30 h prior to
infection with VSVDG virions derived from VSV-XN2 rLuc. Super-
natant was harvested 48 h post-infection, ﬁltered through a
0.45 mm ﬁlter, and stored at 80 1C.
Determination of speciﬁcity of resistance
All infections were done in triplicate. Cells were plated in 24-
well plates at equivalent densities. For VSV EboGP mCherry and
VSV GFP, 2.15106 or 2.35105 plaque forming units (pfu),
respectively, were added to each well. Cells were ﬁxed 12 h later
and analyzed by ﬂow cytometry for mCherry or GFP expression.
For HIV pseudotypes, cells were transduced with equivalent
amounts of virus based on quantitative western blotting with
antibody speciﬁc for HIV-1 p24 (NIH AIDS Research and Reference
Program, Cat#6458). Cells were ﬁxed 48 h post-challenge and
analyzed by ﬂow cytometry for GFP expression.
Flow cytometry
CHO-K1 cells were detached from the plate with phosphate-
buffered saline lacking Caþþ and Mgþþ (PBS/) but containing
0.5 mM EDTA. Cells were pelleted at 4 1C for 2 min at 1100 rpm
then resuspended in ﬂow wash buffer (PBS/ with 1% bovine
calf serum and 0.05% sodium azide) with 2% paraformaldehyde.
For each sample, 10,000 events were collected using a Becton
K.M. Haines et al. / Virology 432 (2012) 20–28 27Dickinson LSRII and analyzed using FlowJo software (Tree
Star, Inc.).
Virus binding assay
CHO cells grown to conﬂuence in 24-well plates were cooled
to 4 1C. Equivalent amounts of particles (based on HIV p24 levels)
were spun onto cells at 1250g for 30 min at 4 1C. Cells were then
washed twice with cold PBS/ and lysed in 30 ml of lysis buffer
(1% Triton X-100, 50 mM Tris pH 8, 5 mM EDTA, 150 mM NaCl)
with complete protease inhibitor cocktail (Roche). Lysates were
cleared by centrifugation at 13,000 rpm for 2 min at 4 1C. Entire
lysates were mixed with reducing SDS buffer, boiled for 5 min,
and separated on a 4–15% Criterion PAGE gel (Bio-Rad). Proteins
were transferred to a PVDF membrane (Millipore). Membranes
were probed with a monoclonal antibody against HIV-1 p24.
Protein was detected with goat anti-mouse IRdye800CW (Rock-
land) and viewed on a LI-COR Odyssey scanner. To determine the
percent of input virus that bound to cells, p24 levels from lysates
were compared to the p24 level in a lane containing the same
amount of virus as was initially added to each well of cells.
Overexpression assays for CatL, CatB, Axl and TIM-1
WT and resistant CHO-K1 cells in 6-well plates were trans-
fected with 1–2 mg of hCathepsinL, hCathepsinB, pSport6 Axl,
pLKO TIM-1, or pcDNA3.1(þ) using Lipofectamine LTX with Plus
reagent. Cells were re-plated into 24-well plates 24 h post-
transfection. At 48 h post-transfection cells were infected with
VSV EboGP mCherry. Cells were ﬁxed 12 h post-infection and
analyzed by ﬂow cytometry for mCherry expression. Protein
expression was conﬁrmed by Western blotting using antibodies
speciﬁc for CatL, CatB (Athens Research and Technology), Axl, or
TIM-1 (R&D Systems).
Generation of stable cell populations expressing human NPC1
WT CHO-K1, M12, and resistant CHO clones were challenged
with HIV pseudotypes bearing VSV G and containing a plenti CMV
NPC1 Hygro vector. At 48 h post-infection transduced cells were
selected with 500 mg/ml Hygromycin B. Stable Hygromycin-resis-
tant cells were subsequently infected with VSV EboGP mCherry
and analyzed by ﬂow cytometry as described above.
Luciferase assay
WT and resistant CHO-K1 cells in 6-well plates were trans-
fected with 1 mg of pcDNA3.1-ACE2 using Lipofectamine LTX and
Plus reagent. Transfected cells were re-plated into 96-well plates
24 h later and infected with equal amounts of VSV/ZEBOV GP or
VSV/SARS S supernatant in triplicate 48 h post-transfection. At
12 h post-infection, media was removed from the wells and
replaced with 20 ul Renilla Luciferase Assay Lysis Buffer (Pro-
mega). Plates were rocked for 30 min before lysates were trans-
ferred to new wells containing 100 ml of Renilla Luciferase Assay
Reagent. Luminescence was measured on a Luminoskan Ascent
(Thermo Electron Corporation) with Ascent 2.5 software.
Statistical analysis
For the luciferase and binding assays, data was analyzed by
repeated measures, two-way ANOVA with Bonferroni post-tests
using GraphPad PRISM software. All other data was analyzed by
permutation test with a signiﬁcance cut off of p¼0.05. Number of
permutations calculated ranged from 67 to 162.Acknowledgments
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